❌

Normal view

Received β€” 26 March 2026 ⏭

TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation

βœ‡Oncogene - Issue - nature.com science feeds
By: Xi Wang Β· Guangyan Li Β· Jiaming Wu Β· Baiyang Fu Β· Haoyang Zhang Β· Yichi Chen Β· Jianjiao Wang Β· Jianguo Zhang Β· Xi Chen
24 March 2026 at 08:00

Oncogene, Published online: 24 March 2026; doi:10.1038/s41388-026-03728-6

TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation

PAK4 functions as an immune suppressor by reprogramming the phosphatidylcholine metabolism of CD8 + T cells within the glioblastoma tumor microenvironment

βœ‡Oncogene - Issue - nature.com science feeds
By: Lin Yao Β· Heyang Gao Β· Zuopeng Su Β· Guozheng Zhao Β· Liyan Tang Β· Shuo Feng Β· Yuting Ma Β· Xiao Zhang Β· Ming Feng Β· Jialiang Qian Β· Yanyan Li Β· Ting Sun Β· Jiangang Liu Β· Hao Wang Β· Youxin Zhou
23 March 2026 at 08:00

Oncogene, Published online: 23 March 2026; doi:10.1038/s41388-026-03734-8

PAK4 functions as an immune suppressor by reprogramming the phosphatidylcholine metabolism of CD8 + T cells within the glioblastoma tumor microenvironment
There are no more articles
❌